Safety and efficacy of eribulin plus anlotinib in patients with advanced soft tissue sarcoma (ERAS): A multi-center phase II study

被引：0
|
作者：
Liu, Jie
Deng, Yaotiao
Wang, Ying
Zhang, Jie
Li, Mei
Jiang, Yu
机构：
[1] Sichuan Univ, West China Hosp, Dept Med Oncol, Ctr Canc, Chengdu, Peoples R China
[2] Chengdu Shang Jin Nan Fu Hosp, Chengdu, Peoples R China
[3] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Dept Oncol, Chengdu, Peoples R China
[4] Chongqing Med Univ, Dept Oncol, Affiliated Hosp 1, Chongqing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11561
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
    Wang, Hai-ying
    Chu, Jun-feng
    Zhang, Peng
    Wang, Jia-qiang
    Yan, Zheng
    Yao, Shu-na
    Yao, Zhi-hua
    Liu, Yan-yan
    ONCOTARGETS AND THERAPY, 2020, 13 : 1561 - 1568
  • [2] Efficacy and safety of apatinib in advanced soft tissue sarcoma: A multi-center, open-label phase II clinical trial.
    Yu, Wenxi
    Fan, Zhengfu
    Chen, Jing
    Zhang, Hong-Mei
    Zhang, Xing
    Qu, Guofan
    Chen, Yong
    Huang, Gang
    Yao, Yang
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Phase II study of eribulin mesylate in patients (pts) with advanced soft tissue sarcoma (STS).
    Naito, Yoichi
    Kawai, Akira
    Araki, Nobuhito
    Ozaki, Toshifumi
    Sugiura, Hideshi
    Yazawa, Yasuo
    Morioka, Hideo
    Matsumine, Akihiko
    Hiraiwa, Masahide
    Asami, Shun
    Isu, Kazuo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Safety and efficacy of eribulin mesylate in patients with advanced soft tissue sarcoma in daily practice
    Inagaki, C.
    Shimoi, T.
    Okuma, H. S.
    Kawachi, A.
    Shimomura, A.
    Noguchi, E.
    Yunokawa, M.
    Yonemori, K.
    Shimizu, C.
    Fujiwara, Y.
    Tamura, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] The efficacy and safety of anlotinib combined with chemotherapy in treatment of advanced soft tissue sarcoma
    Ni, Ying
    Dong, Yabing
    Jiang, Aijun
    Zhang, Qun
    Wang, Zhantong
    Liang, Hui
    Zhang, Wei
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [6] Eribulin mesylate versus eribulin plus anlotinib in patients with advanced or metastatic breast cancer: Results of a phase II study.
    Liu, Liping
    Hu, Zhe-Yu
    Xie, Ning
    Yang, Xiaohong
    Xiao, Huawu
    Li, Jing
    Tian, Can
    Wu, Hui
    Lu, Jun
    Gao, Jianxiang
    Hu, Xuming
    Cao, Min
    Shui, Zhengrong
    Liu, Bingliang
    Ouyang, Quchang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] A prospective, phase II study of tislelizumab administered in combination with eribulin and anlotinib for patients (pts) with advanced adult oft tissue sarcoma (TEASTS)
    Guo, X.
    Zhou, Y.
    Zhuang, R.
    Zhang, C.
    You, Y.
    Li, W.
    Wang, Z.
    ANNALS OF ONCOLOGY, 2024, 35 : S1044 - S1044
  • [8] Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma
    Kawai, Akira
    Araki, Nobuhito
    Naito, Yoichi
    Ozaki, Toshifumi
    Sugiura, Hideshi
    Yazawa, Yasuo
    Morioka, Hideo
    Matsumine, Akihiko
    Saito, Kenichi
    Asami, Shun
    Isu, Kazuo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (02) : 137 - 144
  • [9] Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial
    Tian, Zhichao
    Dong, Shuping
    Zuo, Wenli
    Li, Po
    Zhang, Fan
    Gao, Shilei
    Yang, Yonghao
    Li, Chao
    Zhang, Peng
    Wang, Xin
    Wang, Jiaqiang
    Yao, Weitao
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [10] Efficacy and safety of anlotinib plus TQB2450 in patients with advanced soft tissue sarcoma: A multicenter, single armed, phase 1b trial.
    Liu, Jiayong
    Fan, Zhengfu
    Guo, Wei
    Gao, Tian
    Li, Shu
    Xu, Jie
    Bai, Chujie
    Xue, Ruifeng
    Zhang, Lu
    Xie, Lu
    Tan, Zhichao
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345